Mein Warenkorb

Alpha-fetoprotein

Alpha-fetoprotein Molekülinformation

Englischer NameAlpha-fetoproteinAnzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel6Target-AliasAlpha-Fetoglobulin,AFP,Alpha-fetoprotein,Alpha Fetoprotein,Alpha-1-Fetoprotein,HPAFP,AFPD,FETA,alpha-Fetoproteins
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical
Englischer NameAlpha-fetoprotein
Target-AliasAlpha-Fetoglobulin,AFP,Alpha-fetoprotein,Alpha Fetoprotein,Alpha-1-Fetoprotein,HPAFP,AFPD,FETA,alpha-Fetoproteins
Anzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel6
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical

Alpha-fetoprotein Produktliste

  • Attribut

    Protein (1)

  • Produktbibliothek

    Online (1)

  • Spezies

    Human (1)

  • Etikett

    His Tag (1)

  • Marker

    Unconjugated (1)

ProduktnummerSpeziesExpressionssystemProduktbeschreibungProteinstrukturReinheitEigenschaftenVorbestellen/Bestellen
ALN-H52H9
Human
HEK293
Human Alpha-fetoprotein, His Tag (MALS verified)
In den Warenkorb legen
Gesamtmenge1
  • 1

Alpha-fetoprotein Molekülhintergrund

Alpha-fetoprotein(AFP) is the first tumor marker with clinical application value found by human. AFP has an ability to induce the immune escapes through inhibiting the function of dendritic cells, natural killer cells, and T lymphocytes. By in vitro modification, the immunogenicity and immune response of AFP could be enhanced. AFP-modified immune cell vaccine or peptide vaccine has displayed the specific antitumor immunity against AFP-positive tumor cells and laid a better foundation for the immunotherapy of liver cancer. Alpha-fetoprotein is found in monomeric as well as dimeric and trimeric forms, and binds copper, nickel, fatty acids and bilirubin. The level of alpha-fetoprotein in amniotic fluid is used to measure renal loss of protein to screen for spina bifida and anencephaly.

Alpha-fetoprotein Molekülalias

Alpha-fetoprotein

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
TAEST-1901TAEST-1901Phase 2 ClinicalXiangxue Life Science Technology (Guangdong) Co LtdLiver Neoplasms; Neoplasms; Solid tumours; Stomach Neoplasms
Details
JWATM-203JWATM-203; JWATM203Phase 2 ClinicalSuzhou Yaomingjunuo Biotechnology Co LtdCarcinoma, Hepatocellular
Details
SynOV1.1SynOV1.1Phase 2 ClinicalBeijing Syngentech Co LtdCarcinoma, Hepatocellular; Solid tumours
Details
ET140203Phase 2 ClinicalEureka Therapeutics IncCarcinoma, Hepatocellular; Hepatoblastoma; Liver Neoplasms
Details
CPU-118CPU-118Phase 2 ClinicalChina Pharmaceutical University, Nanjing Qinling Pharmaceutical Technology Co LtdLiver Neoplasms; Neoplasms; Solid tumours
Details
Alpha fetoprotein targeted T-cell therapy (Adaptimmune)AFP TCR (ADP-A2AFP); ADP-A2AFP; AFP TCR; AFPc332TPhase 1 ClinicalAdaptimmune LlcCarcinoma, Hepatocellular
Details
  • Molekülinformation
  • Produktliste
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns